2 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Pertussis: new trials by email Literature Review of Pertussis trials Research Report on Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines Pertagen®, Revaxis® - Pertussis, Vaccine-Preventable Diseases | Phase 2 / Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-02-07 | 2022-01-18 |
| To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years DTaP-IPV combination vaccine - Diphtheria, Tetanus | Phase 3 | Unknown | Boryung Biopharma Co., Ltd. | 249 | 2019-12-26 | 2020-11-06 |
Whooping Cough (2) · Diphtheria (1) · Poliomyelitis (1) · Tetanus (1) · Vaccine-Preventable Diseases (1)
Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Bordetella Infections (2) · Gram-Negative Bacterial Infections (2) · Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Actinomycetales Infections (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Clostridium Infections (1) · Corynebacterium Infections (1) · Enterovirus Infections (1) · Gram-Positive Bacterial Infections (1) · Myelitis (1)
FHD (1)
Boryung Biopharma Co., Ltd. (1) · University Hospital, Geneva (1)
South Korea (1) · Switzerland (1)
Byeonguk Eun (1)